26 patents
Utility
Combinations of Tie-2 Activators and Prostaglandins and Uses Thereof
15 Jul 21
Described herein are combinations of compounds effective for activation of Tie-2 and inhibition of HPTPβ with a compound that causes agonism of a prostaglandin receptor.
Kevin Peters
Filed: 7 Jan 21
Utility
Multispecific Antibodies That Target HPTP-B (Ve-ptp) and Vegf
10 Jun 21
The disclosure provides compositions comprising multi-specific compounds, including a compound that targets a phosphatase and a receptor tyrosine kinase agonist.
Kevin Peters
Filed: 10 Dec 20
Utility
Small Molecule Activators of TIE-2
20 May 21
Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta.
John M. JANUSZ
Filed: 28 Oct 20
Utility
Hptp-beta Inhibitors
6 May 21
Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta.
John Janusz, James Copp, Kevin Peters
Filed: 2 Oct 20
Utility
Methods for Treating Vascular Leak Syndrome and Cancer
1 Apr 21
Disclosed are methods for treating Vascular Leak Syndrome and preventing cancer metastasis.
Kevin Peters, Robert Shalwitz
Filed: 21 Sep 20
Utility
Methods of treating intraocular pressure with activators of Tie-2
23 Mar 21
Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta.
Kevin Gene Peters
Filed: 22 Sep 16
Utility
Multispecific antibodies that target HPTP-β (VE-PTP) and VEGF
19 Jan 21
The disclosure provides compositions comprising multi-specific compounds, including a compound that targets a phosphatase and a receptor tyrosine kinase agonist.
Kevin Peters
Filed: 23 Sep 19
Utility
ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE beta (HPTPbeta) AND USES THEREOF
30 Dec 20
Antibodies and antigen binding fragments thereof that bind to human protein tyrosine phosphatase beta (HPTPβ), and uses thereof.
Rocco Jamie Rotello, Kevin Gene Peters, Michael Glenn Davis
Filed: 6 Feb 20
Utility
Formulations of TIE-2 Activators and Methods of Use Thereof
23 Dec 20
Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTPβ.
Kevin Peters
Filed: 22 Jun 20
Utility
HPTP-Beta inhibitors
7 Dec 20
Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta.
John Janusz, James Copp, Kevin Peters
Filed: 6 May 18
Utility
Compositions, Formulations and Methods for Treating Ocular Diseases
18 Nov 20
Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta.
Kevin Peters, Robert Shalwitz, John Janusz, Alexander Smith
Filed: 28 May 20
Utility
Methods of Treating Hypertension with Activators of TIE-2
11 Nov 20
Disclosed herein are methods for treating hypertension, pulmonary hypertension, and associated conditions using activators of Tie-2 and inhibitors of HPTPβ.
Kevin PETERS
Filed: 15 Apr 20
Utility
TIE-2 Activators Targeting the Schlemm's Canal
28 Oct 20
Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta.
Kevin Peters
Filed: 27 Apr 20
Utility
Methods for treating vascular leak syndrome and cancer
26 Oct 20
Disclosed are methods for treating Vascular Leak Syndrome and preventing cancer metastasis.
Kevin Peters, Robert Shalwitz
Filed: 22 Oct 18
Utility
Methods for Treating Vascular Leak Syndrome
2 Sep 20
Disclosed are methods for treating Vascular Leak Syndrome.
Robert Shalwitz, Kevin Gene Peters
Filed: 12 May 20
Utility
HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-Beta)
26 Aug 20
The disclosure provides compositions and methods for the treatment of ocular conditions associated with angiogenesis comprising administering an antibody that targets a tyrosine phosphatase inhibitor in a subject.
Kevin PETERS, Michael Allen FLYNN
Filed: 16 Apr 20
Utility
Human Protein Tyrosine Phosphatase Inhibitors and Methods of Use
12 Aug 20
The present disclosure relates to compounds effective as human protein tyrosine phosphatase beta (HPTP-β) inhibitors thereby regulating angiogenesis.
Jeffrey Lyle Gray, Kande K.D. Amarasinghe, Cynthia Monesa Clark, Ryan Matthew Nichols, Matthew B. Maier
Filed: 19 Sep 19
Utility
HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-Beta)
29 Jul 20
The disclosure provides compositions and methods for the treatment of ocular conditions associated with angiogenesis comprising administering an antibody that targets a tyrosine phosphatase inhibitor in a subject.
Kevin Peters, Michael Allen Flynn
Filed: 28 Jan 20
Utility
Treatment of Ocular Disease
22 Jul 20
Disclosed are methods for treating eye diseases or conditions characterized by vascular instability, vascular leakage and neovacularization such as diabetic macular edema, age-related macular edema, choroidal neovascularization, diabetic retinopathy, trauma, ocular ischemia, retinal angiomatous proliferation, macular telangiectasia and uveitis.
Kevin Peters, Robert Shalwitz
Filed: 23 Jan 20
Utility
Methods for Treating Vascular Leak Syndrome
1 Jul 20
Disclosed are methods for treating Vascular Leak Syndrome.
Robert Shalwitz, Kevin Gene Peters
Filed: 17 Dec 19